Profile data is unavailable for this security.
About the company
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
- Revenue in INR (TTM)20.89bn
- Net income in INR6.14bn
- Incorporated1990
- Employees990.00
- LocationCaplin Point Laboratories LtdNarbaviNo. 3, Lakshmanan Street,, T. Nagar,CHENNAI 600096IndiaIND
- Phone+91 4 428156653
- Fax+91 4 428154952
- Websitehttps://www.caplinpoint.net/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marksans Pharma Ltd | 28.03bn | 3.60bn | 77.65bn | 1.35k | 21.53 | -- | 16.92 | 2.77 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Strides Pharma Science Ltd | 47.26bn | 5.11bn | 77.65bn | 3.30k | 15.18 | -- | 10.66 | 1.64 | 55.49 | 55.49 | 512.73 | -- | -- | -- | -- | 14,315,680.00 | -- | -0.6014 | -- | -1.09 | 59.34 | 50.33 | 11.23 | -1.06 | -- | 8.50 | -- | -- | 17.36 | 10.65 | 437.22 | 52.50 | 10.08 | -22.16 |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 82.79bn | 1.33k | 28.24 | -- | 26.18 | 6.14 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 87.26bn | 1.24k | 84.23 | -- | 43.35 | 4.11 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Sanofi India Ltd | 18.37bn | 3.27bn | 88.89bn | 991.00 | 27.21 | 11.86 | 24.42 | 4.84 | 141.85 | 141.85 | 797.77 | 325.31 | 1.28 | 2.20 | 9.04 | -- | 22.79 | 24.37 | 39.46 | 36.22 | 51.17 | 53.29 | 17.78 | 22.21 | 0.9951 | 267.06 | 0.0232 | 70.08 | -8.73 | -8.74 | 4.14 | -7.31 | -9.10 | -0.3221 |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 96.63bn | 4.57k | 56.40 | -- | 46.25 | 7.19 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.78bn | 2.40bn | 101.94bn | 583.00 | 42.46 | 26.55 | 40.49 | 11.61 | 104.25 | 104.25 | 381.40 | 166.73 | 1.80 | 4.48 | 40.57 | -- | 49.09 | -- | 66.76 | -- | 73.80 | -- | 27.33 | -- | 3.37 | 148.65 | 0.0607 | -- | 21.24 | -- | 32.65 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.22bn | 2.20k | 20.67 | -- | 18.25 | 4.47 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 115.99bn | 1.21k | 52.26 | -- | 33.78 | 5.65 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.63bn | 1.57k | 40.42 | -- | 33.00 | 10.84 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 127.16bn | 990.00 | 20.78 | -- | 18.35 | 6.09 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 134.67bn | 978.00 | 31.23 | -- | 15.88 | 1.70 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 138.63bn | 16.57k | 22.00 | -- | 14.99 | 1.91 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 142.33bn | 4.07k | 25.55 | -- | 17.29 | 2.80 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 168.02bn | 1.80k | 93.80 | -- | 63.97 | 10.67 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 171.27bn | 4.20k | 11.00 | -- | 9.52 | 3.76 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
Data as of Mar 02 2026. Currency figures normalised to Caplin Point Laboratories Ltd's reporting currency: Indian Rupee INR
5.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 1.35m | 1.78% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 861.80k | 1.13% |
| Principal Global Investors LLCas of 31 Jan 2026 | 717.41k | 0.94% |
| PineBridge Investments Asia Ltd.as of 30 Jun 2025 | 542.69k | 0.71% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 441.90k | 0.58% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 238.87k | 0.31% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 195.60k | 0.26% |
| Mellon Investments Corp.as of 06 Feb 2026 | 98.27k | 0.13% |
| Jennison Associates LLCas of 30 Sep 2025 | 55.00k | 0.07% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 49.77k | 0.07% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
